Key Takeaways
- • DAVIGO AG has acquired a stake in Somatric GmbH, a Munich-based biometric and data analytics technology company, marking the Hamburg-based firm's second private equity investment and demonstrating execution on its announced expansion beyond public equities.
- • Somatric develops a technology platform for real-time human biometric data collection and intelligent analysis, operating in stealth mode with limited public disclosure of specific product developments; the company is led by Jette Schreiber and Niklas Hinz.
- • This investment represents the first private equity deal selected using DAVIGO's proprietary AI-powered digital investment technology, GOLIATH, validating the firm's selection framework based on technological differentiation, early-stage development status, and scalable market potential.
- • Somatric received the Jury Award from the Entrepreneurial Life Science Accelerator (ELSA) in June 2026, underscoring third-party validation of the company's technological merit and providing DAVIGO with early-stage access to a potentially disruptive platform.
- • The investment signals DAVIGO's systematic diversification strategy into unlisted companies and alternative assets, supported by planned capital increases in fiscal year 2026 to fuel portfolio expansion.
Summary
DAVIGO AG, a Hamburg-based investment company, has completed its second private equity investment through the acquisition of a stake in Somatric GmbH, a privately held Munich-based technology firm specializing in biometric measurement and intelligent data analysis. The transaction marks a material step in DAVIGO's announced strategic pivot to expand its investment universe beyond public equities into private company stakes, a shift shareholders approved at the company's annual general meeting.
Somatric operates at the intersection of real-time human biometric data collection and advanced analytics, developing a technology platform designed to unlock previously inaccessible layers of human data for next-generation intelligent applications. The company deliberately maintains a low public profile, withholding granular details about specific product developments. Somatric is led by founders Jette Schreiber and Niklas Hinz and recently achieved industry recognition when it received the Jury Award from the Entrepreneurial Life Science Accelerator (ELSA) in June 2026, validating both its technological approach and market positioning.
Critically, Somatric represents the first deal identified and selected through DAVIGO's proprietary artificial intelligence-powered investment technology platform, GOLIATH. The selection demonstrates the system's ability to operate within a complex decision-making framework, evaluating candidates across three key criteria: technological differentiation of the business model, early-stage company status, and addressable market scalability. According to DAVIGO's statements, this investment provides the firm with early-stage access to what management characterizes as a potentially disruptive technology platform.
DAVIGO intends to finance continued portfolio expansion through planned capital increases in fiscal year 2026, with management signaling its commitment to systematic diversification into unlisted companies as a core strategic objective. The Somatric stake underscores the firm's execution capability in sourcing and closing private equity investments while introducing a new asset class to its shareholder base.
Somatric operates at the intersection of real-time human biometric data collection and advanced analytics, developing a technology platform designed to unlock previously inaccessible layers of human data for next-generation intelligent applications. The company deliberately maintains a low public profile, withholding granular details about specific product developments. Somatric is led by founders Jette Schreiber and Niklas Hinz and recently achieved industry recognition when it received the Jury Award from the Entrepreneurial Life Science Accelerator (ELSA) in June 2026, validating both its technological approach and market positioning.
Critically, Somatric represents the first deal identified and selected through DAVIGO's proprietary artificial intelligence-powered investment technology platform, GOLIATH. The selection demonstrates the system's ability to operate within a complex decision-making framework, evaluating candidates across three key criteria: technological differentiation of the business model, early-stage company status, and addressable market scalability. According to DAVIGO's statements, this investment provides the firm with early-stage access to what management characterizes as a potentially disruptive technology platform.
DAVIGO intends to finance continued portfolio expansion through planned capital increases in fiscal year 2026, with management signaling its commitment to systematic diversification into unlisted companies as a core strategic objective. The Somatric stake underscores the firm's execution capability in sourcing and closing private equity investments while introducing a new asset class to its shareholder base.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.